In addition to products co-developed with our strategic partners or manufactured for our OEM customers, Kensey Nash Corporation (KNC) continues to independently develop new proprietary products in multiple fields of use including orthopaedic (including sports medicine and spine),cardiology, wound repair, aesthetics, and drug delivery, among others.

We are developing several different bone graft substitutes fabricated from collagen, synthetic polymers or composite biomaterials. KNC is also in late pre-clinical study of an in vivo three-dimensional implant for articular cartilage repair and regeneration. The implant, composed of several biomaterials, is architecturally stratified to accommodate the differing components of articular cartilage including the underlying subchondral bone region. Additionally, the implant can be loaded with exogenous proteins or autologous marrow aspirate. In the cardiovascular space, we are conducting pre-clinical study of a synthetic graft that incorporates multiple biomaterials into an “off-the-shelf” implantable prosthesis for coronary and peripheral arterial bypass applications.

Kensey Nash Corporation recently received 510(k) marketing clearance for a proprietary resorbable collagen sheet material intended for use in surgical procedures as a patch for reinforcement and repair of ruptured or damaged soft tissues. Potential applications include a wide variety of general surgical, reconstructive and urogynecologic procedures such as hernia repair, bladder slings for the treatment of stress urinary incontinence, and the repair of pelvic floor defects. We are also advancing development programs using the same base technology for applications in rotator cuff repair, dura repair, bone graft containment, and other procedures.

Biomaterials are particularly useful for the controlled release of drugs and other biologically active agents such as growth factors. Recent advances in polymer delivery system design by KNC have made available the technology to potentially innovate and improve on previous discoveries. We are prototyping a multi-depot drug delivery system and assessing its release characteristics in both laboratory and pre-clinical experimentation. The implant is designed to deliver multiple drugs at a targeted location at controlled rates over time.